Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded at StockNews.com

StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a buy rating to a strong-buy rating in a research report released on Sunday.

Separately, Cantor Fitzgerald reissued a “neutral” rating and issued a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Supernus Pharmaceuticals Stock Up 0.4 %

NASDAQ:SUPN opened at $32.28 on Friday. The company has a fifty day moving average of $36.02 and a 200-day moving average of $35.13. The firm has a market capitalization of $1.80 billion, a P/E ratio of 30.17 and a beta of 0.83. Supernus Pharmaceuticals has a twelve month low of $25.53 and a twelve month high of $40.28.

Insiders Place Their Bets

In related news, VP Padmanabh P. Bhatt sold 9,477 shares of the business’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total value of $376,236.90. Following the transaction, the vice president now directly owns 10,149 shares of the company’s stock, valued at approximately $402,915.30. The trade was a 48.29 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Jonathan Rubin sold 927 shares of the business’s stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the transaction, the senior vice president now directly owns 7,853 shares in the company, valued at $307,444.95. This trade represents a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 11,104 shares of company stock valued at $440,263 in the last three months. 9.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Supernus Pharmaceuticals by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 6,150,759 shares of the specialty pharmaceutical company’s stock worth $222,411,000 after purchasing an additional 22,852 shares during the last quarter. Pacer Advisors Inc. increased its position in shares of Supernus Pharmaceuticals by 29.9% in the third quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock worth $54,655,000 after purchasing an additional 403,028 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Supernus Pharmaceuticals by 1.9% in the fourth quarter. Geode Capital Management LLC now owns 1,510,568 shares of the specialty pharmaceutical company’s stock worth $54,633,000 after purchasing an additional 28,517 shares during the last quarter. American Century Companies Inc. increased its position in shares of Supernus Pharmaceuticals by 9.2% in the fourth quarter. American Century Companies Inc. now owns 1,140,705 shares of the specialty pharmaceutical company’s stock worth $41,248,000 after purchasing an additional 95,777 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Supernus Pharmaceuticals by 5.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 753,363 shares of the specialty pharmaceutical company’s stock worth $27,242,000 after purchasing an additional 40,968 shares during the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.